Short answer
Design Therapeutics, Inc. (DSGN) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$17M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$17M
- −30.4% YoY · +10.9% QoQ
- EPS (diluted)
- −$0.30
- −30.4% YoY · +11.8% QoQ
Source: XBRL data from the Design Therapeutics, Inc. (DSGN) Q3 2025 10-Q on SEC EDGAR. USD.
Design Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- FDA clinical hold on DT-216P2 IND triggered by starting-dose concerns, potentially delaying U.S. clinical development
- DT-216 reformulated after injection-site thrombophlebitis in five Phase 1 MAD patients
- RESTORE-FA update expected in the second half of 2026, with clinical timelines still uncertain
- Cash, cash equivalents and investments of $206.0 million expected to fund operations for more than 12 months
- No product revenue and net loss of $53.8 million for nine months ended September 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Design Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.